Bhargava Narayana Gannavarapu, MD
Gastroenterology · Los Gatos
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 32
- 8 carriers
- Office
- 1
Offices
1 location · Genesis Healthcare Partners PC · 232 clinicians in this group
Hospitals listed: El Camino Health · Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
32 plans · 8 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Gannavarapu’s office at (408) 345-5925 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
32 of 32 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
State licence records
1 licence
- Illinois 036136569Licensed Physician And Surgeon · since 2014 · expires 2029-07-31ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$58,781
Medicare paid this office $58,781 for 173 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 42 | $9,903 | $236 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 19 | $9,805 | $45 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 19 | $7,483 | $57 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 36 | $3,308 | $87 |
| Short return visit (20+ min) | 32 | $3,285 | $80 |
See all 11 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 42 | $9,903 | $236 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 19 | $9,805 | $45 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 19 | $7,483 | $57 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 36 | $3,308 | $87 |
| Short return visit (20+ min) | 32 | $3,285 | $80 |
| Return visit (30+ min) | 22 | $2,981 | $119 |
| New patient visit (30+ min) | 22 | $1,792 | $81 |
| New patient visit (15+ min) | 21 | $1,225 | $58 |
| Biopsy of large bowel using a flexible endoscope | 11 | $1,214 | $110 |
| Short return visit | 14 | $783 | $52 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 12 | $179 | $15 |
Procedures Medicare counted
| Colonoscopy | 26 | More than 51% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 94 | More than 75% of doctors who do this |
Who their Medicare patients are
173 Original Medicare patients in 2024. Average age 73 · Under 65 6% · 85 and older 6% · Women 60% · Also on Medicaid 34% · Health risk score 1.41. At or below the middle of the specialty; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 75% · Diabetes 38% · Coronary heart disease 27% · Depression 23% · Heart failure 17% · Atrial fibrillation 17% · Chronic kidney disease 16% · Dementia 13% · Cancer 11% · COPD 11% · Stroke 9%.
The office billed $333,115, Medicare allowed $76,243 and paid $58,781; for 686 services of 49 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 173 | 686 | 73 | 1.41 | $333,115 | $58,781 |
| 2023 | 284 | 802 | 73 | 1.48 | $415,139 | $75,621 |
| 2022 | 380 | 1,016 | 73 | 1.51 | $403,439 | $105,093 |
| 2021 | 355 | 988 | 75 | 2.22 | $373,871 | $118,746 |
| 2020 | 283 | 736 | 76 | 2.80 | $305,247 | $95,470 |
| 2019 | 378 | 875 | 75 | 2.43 | $300,487 | $113,218 |
| 2018 | 315 | 727 | 71 | 2.66 | $360,357 | $91,982 |
| 2017 | 198 | 464 | 65 | 2.99 | $414,316 | $53,611 |
| 2016 | 90 | 183 | 67 | 2.84 | $190,171 | $25,645 |
| 2015 | 17 | 22 | 68 | 3.45 | $14,107 | $2,710 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 14 services
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 59 | $13,364 | $227 |
| Short return visit (20+ min) | 85 | $7,804 | $77 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 15 | $7,642 | $45 |
| New patient visit (30+ min) | 77 | $6,776 | $88 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 16 | $5,647 | $57 |
| Replacement of stomach stoma tube | 11 | $4,093 | $227 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 45 | $3,770 | $82 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $3,282 | $156 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 14 | $3,094 | $206 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $2,680 | $107 |
| Short return visit | 33 | $1,667 | $51 |
| Return visit (30+ min) | 11 | $1,346 | $122 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 11 | $1,165 | $106 |
| New patient visit (15+ min) | 14 | $919 | $66 |
2022: 14 services
| New patient visit (30+ min) | 209 | $19,598 | $94 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 69 | $15,393 | $220 |
| Short return visit (20+ min) | 118 | $12,322 | $80 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 11 | $6,077 | $45 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 64 | $6,073 | $92 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 11 | $4,331 | $59 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $3,957 | $165 |
| Replacement of stomach stoma tube | 12 | $3,764 | $251 |
| Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | 14 | $2,730 | $195 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 15 | $2,518 | $87 |
| Return visit (30+ min) | 15 | $1,788 | $112 |
| Biopsy of large bowel using a flexible endoscope | 15 | $1,419 | $89 |
| Short return visit | 12 | $727 | $52 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 12 | $61 | $5 |
2021: 14 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 98 | $18,729 | $182 |
| Short return visit (20+ min) | 115 | $14,830 | $84 |
| New patient visit (30+ min) | 97 | $10,060 | $104 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 43 | $9,541 | $222 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 63 | $8,974 | $94 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 67 | $6,092 | $87 |
| Removal of stone or debris from bile or pancreatic duct using a flexible endoscope | 16 | $4,826 | $284 |
| Return visit (30+ min) | 25 | $3,372 | $109 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 26 | $2,458 | $95 |
| Diagnostic exam of large bowel using a flexible endoscope | 12 | $1,969 | $164 |
| Biopsy of large bowel using a flexible endoscope | 21 | $1,850 | $88 |
| Ultrasound exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 14 | $1,782 | $127 |
| New patient visit (15+ min) | 11 | $683 | $62 |
| Incision of pancreatic outlet using a flexible endoscope | 14 | $446 | $32 |
2020: 13 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 127 | $25,235 | $186 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 55 | $7,761 | $97 |
| Return visit (30+ min) | 41 | $5,720 | $100 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 21 | $5,270 | $240 |
| Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 24 | $4,928 | $190 |
| Short return visit (20+ min) | 49 | $4,638 | $69 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 40 | $4,345 | $106 |
| New patient visit (30+ min) | 36 | $3,373 | $94 |
| Ultrasound exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 17 | $2,561 | $151 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 34 | $2,459 | $72 |
| Diagnostic exam of large bowel using a flexible endoscope | 12 | $1,702 | $142 |
| Biopsy of large bowel using a flexible endoscope | 15 | $1,100 | $73 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 19 | $89 | $5 |
2019: 16 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 132 | $25,245 | $183 |
| Short return visit (20+ min) | 83 | $7,778 | $68 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 33 | $7,272 | $220 |
| New patient visit (30+ min) | 67 | $6,455 | $96 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 58 | $5,798 | $98 |
| Removal of stone or debris from bile or pancreatic duct using a flexible endoscope | 21 | $5,523 | $263 |
| Return visit (30+ min) | 26 | $3,414 | $100 |
| Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 18 | $3,393 | $179 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 34 | $3,222 | $95 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 38 | $3,115 | $66 |
| Diagnostic exam of large bowel using a flexible endoscope | 20 | $2,978 | $149 |
| Ultrasound exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 12 | $2,126 | $177 |
| Ultrasound exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 15 | $2,020 | $135 |
| New patient visit (15+ min) | 16 | $923 | $58 |
| Incision of pancreatic outlet using a flexible endoscope | 17 | $852 | $50 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 37 | $166 | $4 |
2018: 16 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 58 | $10,551 | $182 |
| Removal of stone or debris from bile or pancreatic duct using a flexible endoscope | 33 | $7,211 | $206 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 32 | $6,973 | $218 |
| Return visit (30+ min) | 49 | $6,038 | $97 |
| Insertion of stent into pancreatic or bile duct using a flexible endoscope | 12 | $5,203 | $347 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 40 | $3,873 | $97 |
| New patient visit (45+ min) | 26 | $3,801 | $146 |
| New patient visit (30+ min) | 37 | $3,479 | $94 |
| Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 17 | $3,345 | $176 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 31 | $3,024 | $64 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 17 | $2,072 | $122 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 28 | $2,069 | $74 |
| Diagnostic exam of large bowel using a flexible endoscope | 12 | $1,588 | $132 |
| Short return visit (20+ min) | 18 | $1,388 | $69 |
| Incision of pancreatic outlet using a flexible endoscope | 17 | $537 | $32 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 21 | $101 | $5 |
2017: 16 services
| Insertion of stent into pancreatic or bile duct using a flexible endoscope | 12 | $5,289 | $378 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 22 | $4,278 | $194 |
| Removal of stone or debris from bile or pancreatic duct using a flexible endoscope | 26 | $3,624 | $107 |
| Ultrasound exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope through mouth | 20 | $3,040 | $152 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $2,680 | $61 |
| Ultrasound guided needle aspiration or biopsy of esophagus using a flexible endoscope | 12 | $2,427 | $187 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $2,385 | $88 |
| Diagnostic exam of large bowel using a flexible endoscope | 18 | $2,249 | $125 |
| Biopsy of large bowel using a flexible endoscope | 17 | $1,842 | $108 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 25 | $1,839 | $74 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 17 | $1,669 | $98 |
| Return visit (30+ min) | 21 | $1,659 | $66 |
| New patient visit (45+ min) | 14 | $1,556 | $111 |
| Hospital discharge day management, 30 minutes or less | 18 | $1,220 | $61 |
| Short return visit (20+ min) | 16 | $820 | $43 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 29 | $296 | $10 |
2016: 4 services
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 14 | $1,742 | $109 |
| Diagnostic exam of large bowel using a flexible endoscope | 12 | $1,607 | $134 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $851 | $61 |
| Removal of stone or debris from bile or pancreatic duct using a flexible endoscope | 11 | $755 | $63 |
Medicaid work
$0 in 2023
Medicaid paid $0 for 24 billed services this clinician did in 2023, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 24 | $0 |
| 2023 | 24 | 1 | 12 | $0 |
| 2022 | 449 | 4 | 34 | $1,084 |
| 2021 | 410 | 4 | 33 | $2,828 |
| 2020 | 136 | 4 | 22 | $4,350 |
| 2019 | 132 | 3 | 18 | $1,809 |
| 2018 | 62 | 1 | 18 | $1,395 |
See the largest Medicaid services in earlier years
2022
| 1ST HOSP IP/OBS HIGH 75 | 12 | $457 |
| Upper gastrointestinal endoscopy with biopsy | 25 | $354 |
| New patient visit (30+ min) | 224 | $194 |
| Short return visit (20+ min) | 188 | $79 |
2021
| 1ST HOSP IP/OBS HIGH 75 | 62 | $1,674 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 41 | $738 |
| Short return visit (20+ min) | 197 | $291 |
| New patient visit (30+ min) | 110 | $126 |
2020
| 1ST HOSP IP/OBS HIGH 75 | 80 | $2,720 |
| Diagnostic upper gastrointestinal endoscopy | 12 | $1,373 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 17 | $256 |
| Short return visit (20+ min) | 27 | $0 |
2019
| 1ST HOSP IP/OBS HIGH 75 | 80 | $1,667 |
| Short return visit (20+ min) | 39 | $143 |
| New patient visit (30+ min) | 13 | $0 |
2018
| 1ST HOSP IP/OBS HIGH 75 | 62 | $1,395 |
Drugs they prescribed that Part D paid
$36,115
Pharmacies billed $36,115 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 192) in 2024. At or below the middle of the specialty; the typical gastroenterology clinician is at 0%.
170 generic and 22 brand-name prescriptions · $36,115 in drug cost · 11 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Omeprazole | 67 | $964 | $14 |
| Gavilyte-G | 23 | $383 | $17 |
| Ondansetron Odt | 14 | $212 | $15 |
| Peg 3350-Electrolyte | 13 | $201 | $15 |
Year by year
| 2024 | 192 | 99 | 0% (0) | 11% | $36,115 |
| 2023 | 401 | 249 | 0% (0) | 16% | $149,437 |
| 2022 | 521 | 305 | 0% (0) | 34% | $286,563 |
| 2021 | 439 | 216 | 0% (0) | 38% | $154,787 |
| 2020 | 281 | 135 | None | 28% | $178,814 |
| 2019 | 283 | 157 | 0% (0) | 21% | $170,621 |
| 2018 | 175 | 125 | None | 25% | $49,023 |
| 2017 | 94 | 62 | 13% (12) | 23% | $14,884 |
| 2016 | 20 | 16 | None | None | $1,575 |
| 2015 | 79 | 31 | None | 14% | $100,985 |
| 2014 | 97 | 40 | 0% (0) | None | $107,852 |
| 2013 | 82 | 33 | None | 26% | $6,272 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 6 drugs
| Humira(Cf) | 12 | $91,466 | $7,622 |
| Gavilyte-G | 125 | $2,208 | $18 |
| Omeprazole | 96 | $1,585 | $17 |
| Dicyclomine | 23 | $526 | $23 |
| Peg-3350 and Electrolytes | 25 | $463 | $19 |
| Lactulose | 11 | $270 | $25 |
2022: 9 drugs
| Humira(Cf) | 12 | $82,140 | $6,845 |
| Creon | 13 | $39,186 | $3,014 |
| Linzess | 16 | $14,929 | $933 |
| Gavilyte-G | 100 | $1,443 | $14 |
| Peg-3350 and Electrolytes | 85 | $1,251 | $15 |
| Dicyclomine | 48 | $1,231 | $26 |
| Omeprazole | 68 | $1,024 | $15 |
| Pantoprazole | 23 | $473 | $21 |
| Peg 3350-Electrolyte | 11 | $221 | $20 |
2021: 10 drugs
| Creon | 13 | $34,898 | $2,684 |
| Vemlidy | 11 | $13,253 | $1,205 |
| Dexilant | 17 | $8,848 | $520 |
| Suprep | 31 | $3,390 | $109 |
| Dicyclomine | 43 | $1,033 | $24 |
| Omeprazole | 70 | $881 | $13 |
| Peg-3350 and Electrolytes | 58 | $710 | $12 |
| Gavilyte-G | 40 | $541 | $14 |
| Pantoprazole | 19 | $408 | $21 |
| Peg 3350-Electrolyte | 18 | $347 | $19 |
2020: 5 drugs
| Omeprazole | 62 | $610 | $10 |
| Gavilyte-G | 43 | $570 | $13 |
| Pantoprazole | 16 | $412 | $26 |
| Dicyclomine | 18 | $284 | $16 |
| Peg-3350 and Electrolytes | 16 | $190 | $12 |
2019: 5 drugs
| Gavilyte-G | 82 | $1,180 | $14 |
| Omeprazole | 62 | $1,119 | $18 |
| Dicyclomine | 16 | $248 | $16 |
| Pantoprazole | 12 | $211 | $18 |
| Peg-3350 and Electrolytes | 16 | $183 | $11 |
2018: 3 drugs
| Gavilyte-G | 52 | $711 | $14 |
| Omeprazole | 27 | $383 | $14 |
| Peg-3350 and Electrolytes | 14 | $184 | $13 |
2017: 2 drugs
| Gavilyte-G | 25 | $308 | $12 |
| Omeprazole | 16 | $200 | $13 |
2015: 1 drug
| Omeprazole | 23 | $204 | $9 |
Money from drug and device companies
$4,679 in 2025
| 2025 | 13 | 58 | $3,206 | $4,679 |
| 2024 | 15 | 70 | None | $1,238 |
| 2023 | 13 | 54 | None | $1,541 |
| 2022 | 10 | 53 | None | $917 |
| 2021 | 11 | 89 | $19,420 | $20,692 |
| 2020 | 9 | 37 | $2,100 | $2,750 |
| 2019 | 7 | 32 | None | $1,045 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Olympus Medical Systems | Evis Exera II Small Intestinal Videoscope | $3,206 | 1 payment
|
| Abbvie | Rinvoq | $424 | 22 payments
|
| Janssen Biotech | Tremfya | $269 | 10 payments
|
| Boston Scientific | Axios | $257 | 2 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $103 | 5 payments
|
| Celltrion USA | Vegzelma | $98 | 5 payments
|
See all 58 published payments
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-12-21 | Xifaxan | $20 |
| Janssen Biotech | Meals · 2025-12-16 | Tremfya | $6 |
| Ardelyx | Meals · 2025-12-03 | Ibsrela | $22 |
| Celltrion USA | Meals · 2025-11-18 | Vegzelma | $20 |
| Gilead Sciences | Meals · 2025-11-07 | None | $23 |
| Abbvie | Meals · 2025-11-06 | Creon | $8 |
| Abbvie | Meals · 2025-10-30 | Creon | $25 |
| Abbvie | Meals · 2025-10-22 | Creon | $9 |
| Abbvie | Meals · 2025-10-21 | Skyrizi | $24 |
| Abbvie | Meals · 2025-10-15 | Viberzi | $26 |
| Janssen Biotech | Meals · 2025-10-01 | Tremfya | $8 |
| Gilead Sciences | Meals · 2025-09-18 | None | $26 |
| Abbvie | Meals · 2025-09-16 | Rinvoq | $28 |
| Abbvie | Meals · 2025-09-10 | Creon | $26 |
| Boston Scientific | Meals · 2025-09-09 | Axios | $128 |
| Boston Scientific | Meals · 2025-09-09 | Axios | $128 |
| Abbvie | Meals · 2025-08-28 | Viberzi | $25 |
| Abbvie | Meals · 2025-08-13 | Rinvoq | $25 |
| Abbvie | Meals · 2025-08-08 | Linzess | $20 |
| Gilead Sciences | Meals · 2025-08-06 | None | $25 |
| Abbvie | Meals · 2025-07-31 | Viberzi | $6 |
| Celltrion USA | Meals · 2025-07-31 | Vegzelma | $24 |
| Abbvie | Meals · 2025-07-30 | Rinvoq | $23 |
| Abbvie | Meals · 2025-07-18 | Creon | $2 |
| Abbvie | Meals · 2025-07-18 | Creon | $20 |
| Janssen Biotech | Education · 2025-07-16 | Tremfya | $99 |
| Janssen Biotech | Meals · 2025-07-15 | Tremfya | $27 |
| Abbvie | Meals · 2025-07-09 | Rinvoq | $26 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-07-09 | Xifaxan | $23 |
| Olympus Medical Systems | Consulting · 2025-06-29 | Evis Exera II Small Intestinal Videoscope | $3,206 |
| Pfizer | Meals · 2025-06-24 | Xeljanz | $16 |
| Janssen Biotech | Meals · 2025-06-10 | Tremfya | $19 |
| Celltrion USA | Meals · 2025-06-05 | Vegzelma | $16 |
| Braintree Laboratories | Meals · 2025-06-03 | Sutab | $45 |
| Madrigal Pharmaceuticals | Meals · 2025-05-27 | Rezdiffra | $22 |
| Vivus | Meals · 2025-05-06 | Pancreaze | $24 |
| Abbvie | Meals · 2025-05-06 | Linzess | $12 |
| Abbvie | Meals · 2025-05-05 | Rinvoq | $24 |
| Janssen Biotech | Meals · 2025-04-30 | Tremfya | $20 |
| Abbvie | Meals · 2025-04-22 | Skyrizi | $23 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-04-16 | Entyvio | $27 |
| Celltrion USA | Meals · 2025-04-08 | Vegzelma | $19 |
| Vivus | Meals · 2025-04-03 | Pancreaze | $25 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2025-03-26 | Eohilia | $26 |
| Abbvie | Meals · 2025-03-20 | Viberzi | $27 |
| Abbvie | Meals · 2025-03-15 | Linzess | $7 |
| Abbvie | Meals · 2025-03-12 | Rinvoq | $26 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-03-06 | Xifaxan | $15 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-02-28 | Xifaxan | $24 |
| Janssen Biotech | Meals · 2025-02-25 | Tremfya | $26 |
| Janssen Biotech | Meals · 2025-02-25 | Tremfya | $6 |
| Abbvie | Meals · 2025-02-25 | Linzess | $12 |
| Gilead Sciences | Meals · 2025-02-19 | None | $14 |
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-02-12 | Xifaxan | $21 |
| Janssen Biotech | Meals · 2025-01-28 | Tremfya | $25 |
| Celltrion USA | Meals · 2025-01-22 | Vegzelma | $20 |
| Janssen Biotech | Meals · 2025-01-14 | Tremfya | $32 |
| Madrigal Pharmaceuticals | Meals · 2025-01-08 | Rezdiffra | $25 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,238
| Abbvie | Linzess | $375 | 23 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $191 | 15 payments
|
| Gilead Sciences | None | $189 | 10 payments
|
| Pfizer | Xeljanz | $101 | 4 payments
|
| Janssen Biotech | Tremfya | $79 | 3 payments
|
| Celltrion USA | Vegzelma | $54 | 2 payments
|
| Ipsen Biopharmaceuticals | Iqirvo | $47 | 2 payments
|
| Intercept Pharmaceuticals | Ocaliva | $45 | 2 payments
|
| Braintree Laboratories | Sutab | $41 | 2 payments
|
| Micro-tech Endoscopy USA | Biopsy Forceps | $31 | 2 payments
|
| Phathom Pharmaceuticals | Voquezna | $29 | 1 payment
|
| Ironwood Pharmaceuticals | Linzess | $20 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $17 | 1 payment
|
| Lilly USA | Omvoh | $14 | 1 payment
|
| Endogastric Solutions | Esophyx | $7 | 1 payment
|
2023: $1,541
| Boston Scientific | Exalt Model D | $580 | 6 payments
|
| Abbvie | Rinvoq | $331 | 23 payments
|
| Celgene | Zeposia | $155 | 3 payments
|
| Gilead Sciences | None | $153 | 8 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $63 | 3 payments
|
| Intercept Pharmaceuticals | Ocaliva | $54 | 2 payments
|
| Celltrion USA | Yuflyma | $53 | 2 payments
|
| Janssen Biotech | Stelara | $43 | 2 payments
|
| Aimmune Therapeutics | Vowst | $35 | 1 payment
|
| Braintree Laboratories | Suflave | $23 | 1 payment
|
| Micro-tech Endoscopy USA | Lockado | $18 | 1 payment
|
| Lilly USA | None | $18 | 1 payment
|
| RedHill Biopharma | None | $15 | 1 payment
|
2022: $917
| Abbvie | Mavyret | $349 | 21 payments
|
| Gilead Sciences | None | $176 | 13 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $146 | 11 payments
|
| Boston Scientific | Exalt Model D | $77 | 1 payment
|
| Janssen Biotech | Remicade | $37 | 1 payment
|
| RedHill Biopharma | Talicia | $36 | 2 payments
|
| Pfizer | Xeljanz | $27 | 1 payment
|
| Merck Sharp & Dohme | Dificid | $24 | 1 payment
|
| Braintree Laboratories | Sutab | $23 | 1 payment
|
| Ironwood Pharmaceuticals | Linzess | $22 | 1 payment
|
2021: $20,692
| CapsoVision | Capsocam Colon | $19,420 | 2 payments
|
| AbbVie | Humira | $503 | 34 payments
|
| Gilead Sciences | None | $197 | 16 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $185 | 15 payments
|
| RedHill Biopharma | Talicia | $111 | 7 payments
|
| Nestle HealthCare Nutrition | Zenpep | $111 | 6 payments
|
| Ironwood Pharmaceuticals | Linzess | $53 | 3 payments
|
| Braintree Laboratories | Sutab | $40 | 2 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $32 | 2 payments
|
| Alfasigma USA | Zelnorm | $21 | 1 payment
|
| Daiichi Sankyo | Injectafer | $20 | 1 payment
|
2020: $2,750
| CapsoVision | None | $2,100 | 1 payment
|
| Gilead Sciences | None | $266 | 18 payments
|
| AbbVie | Humira | $223 | 10 payments
|
| Braintree Laboratories | Suprep Bowel Prep | $37 | 2 payments
|
| RedHill Biopharma | Talicia | $33 | 2 payments
|
| Nestle HealthCare Nutrition | Zenpep | $24 | 1 payment
|
| Alfasigma USA | Zelnorm | $24 | 1 payment
|
| Merck Sharp & Dohme | Dificid | $21 | 1 payment
|
| Coloplast | Continence Care | $21 | 1 payment
|
2019: $1,045
| Boston Scientific | Axios | $606 | 10 payments
|
| AbbVie | Mavyret | $167 | 12 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $119 | 1 payment
|
| Shionogi | Mulpleta | $63 | 3 payments
|
| Takeda Pharmaceuticals U.S.A. | Entyvio | $55 | 3 payments
|
| Gilead Sciences | None | $29 | 2 payments
|
| Apollo Endosurgery US | Overstitch | $8 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study To Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Crohn'S Disease · 2021 | Their institution | $13,938 |
| Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study To Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Crohn'S Disease · 2022 | Their institution | $11,165 |
| Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study To Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Crohn'S Disease · 2020 | This clinician | $9,920 |
| Eli Lilly and Company · A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study To Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately To Severely Active Crohn'S Disease · 2020 | Their institution | $5,833 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 84.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1881821825
- Licence
- IL 036136569Illinois 036136569: Active
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X); Internal medicine (207R00000X)
- Mailing address
- 200 Jose Figueres Ave Ste 170, San Jose, CA, 95116
- NPI first listed
- 2009-06-17
- NPI last updated
- 2022-10-12
- NPI record certified
- 2022-10-12
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 675 N Saint Clair St, Chicago, IL, 60611